A phase II study of naloxone nasal spray for the treatment of opioid overdose reversal

Trial Profile

A phase II study of naloxone nasal spray for the treatment of opioid overdose reversal

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Naloxone (Primary)
  • Indications Opioid abuse
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2016 According to a Lightlake therapeutics media release, the company plans to report top-line results of this trial in H1 2017.
    • 06 May 2016 According to a Adapt Pharma Limited media release, the company has done a new drug submission (NDS) of naloxone nasal spray to Health Canada for the emergency reversal of opioid overdose.
    • 19 Nov 2015 According to a Adapt Pharma Limited media release, the U.S. Food and Drug Administration (FDA) has approved NARCAN (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top